SYK

Knight Therapeutics Announces Regulatory Submission of Fostamatinib in Brazil

Retrieved on: 
Wednesday, February 21, 2024

MONTREAL, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate, United Medical Ltda., has submitted a marketing authorization application to ANVISA, the Brazilian health regulatory agency, for fostamatinib for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.

Key Points: 
  • MONTREAL, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate, United Medical Ltda., has submitted a marketing authorization application to ANVISA, the Brazilian health regulatory agency, for fostamatinib for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.
  • Knight has previously submitted marketing authorization applications for fostamatinib in Colombia and Mexico.
  • “This submission of fostamatinib demonstrates Knight’s continued execution of our strategy of leveraging our solid platform and expertise to bring innovative therapies for important unmet healthcare needs in Latin America,” said Samira Sakhia, President and Chief Executive Officer of Knight Therapeutics Inc.
    On May 24, 2022, Knight announced that it entered into an agreement with Rigel Pharmaceuticals, Inc. for the exclusive rights to commercialize fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor, in Latin America.
  • Fostamatinib is commercially available in the United States under the brand name TAVALISSE® and in Europe under the brand name TAVLESSE® for the treatment of adult chronic ITP.

First shoulder arthroplasty surgeries using Stryker’s Blueprint® Mixed Reality Guidance System completed in Europe

Retrieved on: 
Wednesday, February 28, 2024

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240227354011/en/
    Stryker's Blueprint Mixed Reality Guidance System offers shoulder arthroplasty surgeons a new tool to execute their pre-operative plan.
  • (Photo: Business Wire)
    “It’s exciting to be one of the first two hospitals in Europe to use Stryker’s Mixed Reality Guidance System,” said Professor Berhouet.
  • Blueprint Mixed Reality Guidance System allows surgeons and their instruments to be ‘guided’ by 3D images and guidance widgets, which can be displayed on the patient and in the surgeon’s line of sight without disrupting normal workflow.
  • The MR Guidance system received a CE mark at the end of 2023 and the first surgeries globally were performed in the U.S. and Canada in December 2023.

Stryker showcases commitment to innovation at AAOS 2024 Annual Meeting

Retrieved on: 
Tuesday, February 13, 2024

MAHWAH, N.J., Feb. 13, 2024 /PRNewswire/ -- Stryker (NYSE: SYK), a global leader in medical technology, showcases its commitment to innovation and technological advancement in Joint Replacement with the introduction of Triathlon® Hinge as well as the continued evolution of Mako SmartRobotics™ at this year's American Academy of Orthopaedic Surgeons' (AAOS) 2024 Annual Meeting in San Francisco.

Key Points: 
  • MAHWAH, N.J., Feb. 13, 2024 /PRNewswire/ -- Stryker (NYSE: SYK), a global leader in medical technology, showcases its commitment to innovation and technological advancement in Joint Replacement with the introduction of Triathlon® Hinge as well as the continued evolution of Mako SmartRobotics™ at this year's American Academy of Orthopaedic Surgeons' (AAOS) 2024 Annual Meeting in San Francisco.
  • The foundation of the Triathlon Hinge system is the versatility of the Triathlon Revision Baseplate, with multiple intraoperative and post-operative revision knee implant options, allowing for seamless conversion to any Stryker revision procedure.
  • AAOS 2024 Annual Meeting attendees can visit Stryker's booth (#5945) to learn more.
  • Stryker will also hold demonstrations, exhibitions and a symposium throughout the AAOS 2024 Annual Meeting.

Stryker declares a $0.80 per share quarterly dividend

Retrieved on: 
Wednesday, February 7, 2024

Portage, Michigan, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that its Board of Directors has declared a quarterly dividend of $0.80 per share payable April 30, 2024 to shareholders of record at the close of business on March 29, 2024, representing an increase of 6.7% versus the prior year and unchanged from the previous quarter.

Key Points: 
  • Portage, Michigan, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that its Board of Directors has declared a quarterly dividend of $0.80 per share payable April 30, 2024 to shareholders of record at the close of business on March 29, 2024, representing an increase of 6.7% versus the prior year and unchanged from the previous quarter.

Stryker to participate in Citi’s 2024 Unplugged Medtech and Life Sciences Access Day

Retrieved on: 
Monday, February 5, 2024

Portage, Michigan, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) will participate in Citi’s 2024 Unplugged Medtech and Life Sciences Access Day on Thursday, February 29, 2024 at Citigroup Headquarters, New York, New York.

Key Points: 
  • Portage, Michigan, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) will participate in Citi’s 2024 Unplugged Medtech and Life Sciences Access Day on Thursday, February 29, 2024 at Citigroup Headquarters, New York, New York.
  • Glenn Boehnlein, Vice President, Chief Financial Officer and Jason Beach, Vice President, Investor Relations will represent the Company in a presentation scheduled for 1:45 p.m. Eastern Time.
  • A simultaneous webcast and replay of the Company’s presentation will be available on Stryker’s website at www.stryker.com .
  • The webcast will be archived on the Investor Relations page of this site.

Stryker Expands Prophecy® Surgical Planning System to Include the New Footprint™, Offering Surgeons a Comprehensive View of the Foot and Ankle

Retrieved on: 
Wednesday, January 31, 2024

Stryker (NYSE: SYK), a global leader in medical technologies, today announced the launch of Prophecy Footprint, an expansion of the Prophecy Surgical Planning system, offering comprehensive surgical planning across the entire foot.

Key Points: 
  • Stryker (NYSE: SYK), a global leader in medical technologies, today announced the launch of Prophecy Footprint, an expansion of the Prophecy Surgical Planning system, offering comprehensive surgical planning across the entire foot.
  • The system will be demonstrated at the American College of Foot and Ankle Surgeons (ACFAS) Annual Meeting , Tampa Bay, Fla., Feb. 1-4 (booth #919).
  • The launch of Prophecy Footprint also coincides with the tenth anniversary of Stryker’s Infinity Total Ankle System, a low-profile implant indicated for total ankle replacement in patients with end-stage ankle arthritis.
  • Prophecy Footprint elevates surgical planning by providing comprehensive procedural considerations that address concomitant pathology at the time of total ankle arthroplasty.

New Intermediate Nail and RC Lag Screw Expand Gamma4 Portfolio to Meet the Needs of Surgeons and Their Patients

Retrieved on: 
Wednesday, January 17, 2024

“Stryker remains unwavering in our commitment to providing cutting-edge orthopaedic solutions to meet the needs of our customers.

Key Points: 
  • “Stryker remains unwavering in our commitment to providing cutting-edge orthopaedic solutions to meet the needs of our customers.
  • The recent line extension, including the Gamma4 intermediate nail and RC Lag Screw, received 510(k) clearance in June 2023.
  • Hip fractures with involvement of the basicervical neck region can be provisionally stabilized with the anti-rotation clip and sleeve during lag screw insertion.
  • The Phase 2 launch of these additional Gamma4 features will expand the surgeon's toolbox and add to an already best-of-class nailing system.”

First Shoulder Arthroplasty Surgeries Using Stryker’s Blueprint® Mixed Reality Guidance System Completed at Mayo Clinic in Minnesota and at St. Joseph’s Health Care London in Canada

Retrieved on: 
Wednesday, January 10, 2024

Stryker (NYSE:SYK), one of the world’s leading medical technology companies, today announced that the first shoulder arthroplasty surgeries using Blueprint® Mixed Reality (MR) Guidance have been successfully completed by Dr. Joaquin Sanchez-Sotelo, MD, PhD, Consultant and Professor of Orthopedic Surgery at Mayo Clinic in Rochester, Minn., and Dr. George Athwal at St. Joseph’s Health Care London, Canada.

Key Points: 
  • Stryker (NYSE:SYK), one of the world’s leading medical technology companies, today announced that the first shoulder arthroplasty surgeries using Blueprint® Mixed Reality (MR) Guidance have been successfully completed by Dr. Joaquin Sanchez-Sotelo, MD, PhD, Consultant and Professor of Orthopedic Surgery at Mayo Clinic in Rochester, Minn., and Dr. George Athwal at St. Joseph’s Health Care London, Canada.
  • (Photo: Business Wire)
    “Mixed reality technology offers important benefits to patients,” said Dr. Sanchez-Sotelo, one of the Blueprint design surgeons.
  • “The addition of Mixed Reality Guidance to our Blueprint platform has the potential to benefit the entire shoulder arthroplasty market – surgeons and patients alike,” said Tim Lanier, president of Stryker’s Trauma & Extremities division.
  • Stryker anticipates the completion of the first case utilizing the Blueprint® Mixed Reality (MR) Guidance System in Europe in February, marking a significant milestone in advancing surgical technology globally.

Stryker announces 2023 sales surpassed $20 billion

Retrieved on: 
Monday, January 8, 2024

Portage, Michigan, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced today that it surpassed $20 billion in annual sales for the first time in its history during the month of December, 2023.

Key Points: 
  • Portage, Michigan, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced today that it surpassed $20 billion in annual sales for the first time in its history during the month of December, 2023.
  • “We are excited to surpass this major milestone and to share with our employees as we have our kick-off meetings for 2024,” said Kevin Lobo, Chair and Chief Executive Officer.
  • “This means that we are positively impacting more customers and patients than ever.”
    Stryker will disclose additional information regarding its 2023 financial results during its Q4 and Full Year Earnings Call, scheduled for January 30, 2024.

Stryker to announce financial results for its fourth quarter and full year 2023

Retrieved on: 
Friday, January 5, 2024

Portage, Michigan, Jan. 05, 2024 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that it will report financial results for fourth quarter and full year 2023 on Tuesday, January 30, 2024.

Key Points: 
  • Portage, Michigan, Jan. 05, 2024 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that it will report financial results for fourth quarter and full year 2023 on Tuesday, January 30, 2024.
  • A press release will be issued at approximately 4:05pm ET and available at Stryker - Press Releases that day.
  • The press release will include summary financial information for the company’s fourth quarter and full year 2023, that ended December 31, 2023.
  • Stryker will host a webcast at 4:30pm ET on Tuesday, January 30, 2024, to discuss results for its fourth quarter and full year 2023.